000			02047 a2200553 4500
005			20250517164058.0
264		0	_c20181227
008			201812s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-017-0491-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aWeiss, Glen J
245	0	0	_aPhase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. _h[electronic resource]
260			_bInvestigational new drugs _c02 2018
300			_a85-95 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aCell Cycle Proteins _xantagonists & inhibitors
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aProtein Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aProto-Oncogene Proteins _xantagonists & inhibitors
650	0	4	_aThrombocytopenia _xchemically induced
650	0	4	_aTreatment Outcome
650	0	4	_aPolo-Like Kinase 1
700	1		_aJameson, Gayle
700	1		_aVon Hoff, Daniel D
700	1		_aValsasina, Barbara
700	1		_aDavite, Cristina
700	1		_aDi Giulio, Claudia
700	1		_aFiorentini, Francesco
700	1		_aAlzani, Rachele
700	1		_aCarpinelli, Patrizia
700	1		_aDi Sanzo, Alessandro
700	1		_aGalvani, Arturo
700	1		_aIsacchi, Antonella
700	1		_aRamanathan, Ramesh K
773	0		_tInvestigational new drugs _gvol. 36 _gno. 1 _gp. 85-95
856	4	0	_uhttps://doi.org/10.1007/s10637-017-0491-7 _zAvailable from publisher's website
999			_c27385418 _d27385418